CONTENT BLOCKED PENDING BUSINESS CONFIRMATION. The catalogue lists benefits consistent with an incretin-class agent – weight, glycaemic control, cardiovascular and inflammatory effects – but does not state the active substance. Note for the commercial team: the 5 mg B2B price matches the Tirzepatide 5 mg line in the pricing workbook, while the 10 mg price does not match any line, so the mapping cannot be inferred with confidence. If this product contains a licensed molecule such as tirzepatide or semaglutide, then prescription-medicine advertising restrictions, off-label supply rules and originator intellectual property all apply and legal review is required before any listing.
Active Compound: ACTIVE COMPOSITION NOT STATED IN SOURCE CATALOGUE - CONFIRMATION REQUIRED
Permitted Claim GuidelinesNone. Do not publish any content for this SKU until composition is confirmed.
Mechanism of ActionBLOCKED - Active composition required.
Evidence Grade: BLOCKED - Cannot be assessed without stated active
Clinical Evidence BaseBLOCKED - Active composition required.
Literature & ReferencesBLOCKED - Active composition required.
Safety & PrecautionsBLOCKED - Active composition required. If this product contains an incretin-class agonist, the class safety profile applies in full, including gastrointestinal effects, pancreatitis and gallbladder risk, thyroid C-cell contraindications and pregnancy contraindication.
ContraindicationsBLOCKED - Active composition required.
Storage & HandlingStore lyophilised vial at 2-8 C, protected from light.
Regulatory StatusBLOCKED. If the active is a licensed medicine, supply and promotion are subject to prescription-medicine controls in every target market. Do not list until composition is confirmed and legally reviewed.